Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
AstraZeneca Announces First Direct-to-Patient Program Offering the brand ARIMIDEX Tablets to patients for only $40 per month
AstraZeneca Press Release (02/16/12)
AstraZeneca has announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts for $40 per month. “ARIMIDEX Direct marks a first for AstraZeneca,” said Steve Davis, Executive Director, Foundation Brands, AstraZeneca. “We believe it is also the first time eligible patients have a nationwide direct-to-patient option. The program offers the brand ARIMIDEX at the low cost of $40 per month via home delivery,” Davis continued. “It is an important new way for AstraZeneca to help meet U.S. customer needs.”
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
